Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
BeovuⓇ - VEGF Inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milestone(s)
Publication
NCT03481634 KESTREL (CRTH258B2301)
Diabetic eye disease
Phase 3
534
Change from baseline in best-corrected visual acuity (BCVA)
Brolucizumab (RTH258) 3 mg/50 μL
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2mg/50 uL
Patients with visual impairment due to diabetic macular edema (DME)
Primary: Q4-2020 (actual); Final: Q4-2021
Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 (Actual)
NCT03481660 KITE (CRTH258B2302)
Diabetic eye disease
Phase 3
356
Change from baseline in best-corrected visual acuity (BCVA)
Brolucizumab (RTH258) 6 mg/50 μL
Aflibercept 2 mg/50 μL
Patients with visual impairment due to diabetic macular edema (DME)
Primary: Q3-2020 (actual); Final: Q3-2021 (actual).
Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 (Actual)
106 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation